Pain, Sleep Latency, and Mental and Physical Health in Individuals with Self-Reported Hypermobile Ehlers-Danlos Syndrome
Abstract
Background: Individuals with hypermobile Ehlers-Danlos syndrome (hEDS) frequently report chronic pain, sleep-related complaints, and reduced mental and physical health. While sleep disturbance has been described in this population, less is known about how pain frequency relates to sleep initiation and broader health burden. This study aimed to examine the associations between pain frequency, sleep latency, and mental and physical health burden in individuals with hEDS. Methods: This analysis used cross-sectional survey data collected from adults with self-reported EDS. Pain frequency was treated as an ordinal variable. Sleep disturbance was assessed via self-reported sleep latency, and mental and physical health burden were defined as reporting 14 or more days of poor health in the prior 30 days. Ordinal logistic regression was used to examine associations between pain frequency and sleep latency, adjusting for age group. Binary logistic regression models examined associations between pain frequency and mental and physical health burden. Results: A total of 2365 respondents with self-reported hEDS were included in the analysis. Increasing pain frequency was associated with progressively longer sleep latency, demonstrating a clear dose-response relationship (p p p Conclusions: Pain frequency was significantly associated with longer sleep latency and overall health burden in individuals with hEDS. These findings suggest that pain and sleep disturbance are interconnected…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.